FDA drug approvals are on track with last year's tally by 2Q13. Apart from MannKind's inhaled insulin, Merck's PAR-1 antagonist with its potential safety benefit and long-acting versions of GLP-1 and Factor VIII were approved. A slew of hepatitis C drugs in various combinations is moving toward registration. New breakthrough drug designations include the first chimeric antigen receptor (CAR) T-cell therapy and gene therapy to receive the designation. This new category for drug review seems to be in favor both at the FDA and in companies.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 2Q14. Nat Biotechnol 32, 710 (2014). https://doi.org/10.1038/nbt.2990
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2990
